Eventide Asset Management, LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Eventide Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.85 - $16.83 $2.72 Million - $4.65 Million	276,200 New	276,200 $4.01 Million
Q1 2022 May 16, 2022	SELL	$11.2 - $16.97 $1.55 Million - $2.36 Million	-138,821 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $6.51 Million - $9.63 Million	-526,860 Reduced 79.15%	138,821 $1.84 Million
Q2 2021 Aug 16, 2021	SELL	$23.12 - $29.91 $16.4 Million - $21.2 Million	-707,319 Reduced 51.52%	665,681 $16 Million
Q1 2021 May 14, 2021	SELL	$14.69 - $42.57 $4.51 Million - $13.1 Million	-307,000 Reduced 18.27%	1,373,000 $35.3 Million
Q3 2019 Nov 21, 2019	BUY	$11.6 - $21.67 $2.09 Million - $3.9 Million	180,000 Added 12.0%	1,680,000 $19.5 Million
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $11.1 Million - $18.5 Million	600,000 Added 66.67%	1,500,000 $33.2 Million
Q1 2018 May 15, 2018	BUY	$9.22 - $12.35 $1.76 Million - $2.36 Million	191,000 Added 26.94%	900,000 $8.53 Million
Q4 2017 Feb 14, 2018	BUY	$6.8 - $13.54 $2.13 Million - $4.24 Million	313,000 Added 79.04%	709,000 $6.91 Million
Q3 2017 Nov 14, 2017	BUY	$5.84 - $8.88 $2.31 Million - $3.52 Million	396,000	396,000 $2.64 Million

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.